TIMID

T cell driven Immune Mediated Inflammatory Diseases

Read About Us

What we do

Immune mediated inflammatory diseases (IMIDs) such as diabetes type I, spondyloarthritis, juvenile idiopathic arthritis, celiac disease, inflammatory bowel disease, graft versus host disease and colon cancer are a result of inappropriately regulated immune responses. The severity of disease strongly varies from patient to patient. As a result, response to treatment is also highly variable. With the TIMID consortium we are investigating which immune patterns are shared by patients an IMID independent of their diseased organ. Based on this in depth analysis of immune responses we anticipate to find subgroups of patients with distinct immune profiles and aim to classify these IMIDs on the basis of this immune response. This research should provide new targets to more precisely intervene in the patients’ defective immune response.

Who are we?

The TIMID project provides a unique opportunity for bringing together a diverse team of experts in the field of immune mediated inflammatory diseases (IMIDs), and it consists of renowned scientists from 6 Dutch universities and 5 companies.

Information for the public

The study conducted by the TIMID Consortium is led by Dr. Janneke Samsom (Erasmus MC) and Prof. Dr. Frits Koning (LUMC): “The major problem with chronic immune diseases is that the disease can vary from patient to patient and is therefore difficult to treat”.

Would you like to understand more about the TIMID project?
Check the links below:

 

Information for the public (ENGLISH)
INFORMATIE VOOR HET PUBLIEK (NEDERLANDS)

Our Scientific collaborators

TIMID sponsors